Peptide Initiative

Dosing protocol · Cognitive

N-Acetyl Selank dosing & administration

Acetylated tuftsin analogue heptapeptide with enhanced stability and anxiolytic, nootropic, and immunomodulatory properties acting through GABAergic modulation and BDNF upregulation

Suggested dose

250 – 2,700 mcg/day

Once dailyFrequency
IntranasalRoute
4-6 weeksCycle length

Dosing

How much N-Acetyl Selank do I take?

Intranasal

Intranasal: Sprayed into the nose, where it absorbs through the nasal lining.

Bioavailability Moderate — absorbs through the nasal lining and can partly bypass the gut.

3 documented dose levels — separate regimens, not a titration schedule

  • 250-300 mcg/day

    Frequency
    Divided 2-3 times daily
    Duration
    1-2 weeks initial

    Lower end of the intranasal range used in Russian anxiolytic research; intranasal is the optimal CNS-delivery route for Selank .

  • 300-900 mcg/day

    Frequency
    Divided 2-3 times daily (100-300 mcg per dose)
    Duration
    2-4 weeks per course

    Daily intranasal range documented in Russian GAD trials, with anxiolytic effects comparable to medazepam .

  • Up to 2700 mcg/day

    Frequency
    Divided 2-3 times daily
    Duration
    2-4 weeks per course

    Upper intranasal dose reported in a generalized anxiety disorder cohort ; used short-course.

Timing

Best time to take

Administer N-Acetyl Selank nasal spray at the same time each day. Morning dosing is commonly preferred. Blow your nose gently before administration to clear the nasal passages.

With food?

N-Acetyl Selank nasal administration is not significantly affected by food. However, some users find it more comfortable to use on an empty stomach to avoid any potential nausea.

If stacking

N-Acetyl Selank should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting your dose

Increase if

  • You've tolerated the current dose for the recommended period without significant side effects
  • Therapeutic goals haven't been met at the current dose level
  • Your healthcare provider recommends dose escalation based on your response
  • Lab work or clinical assessments support a higher dose

Decrease if

  • Side effects are bothersome or impacting daily life despite management strategies
  • You experience any signs of an adverse reaction
  • Lab results indicate the need for dose reduction
  • Your healthcare provider recommends a lower dose based on your response

Signs of right dose

  • Therapeutic goals being met with minimal side effects
  • Stable and consistent response to treatment
  • Lab values or clinical markers trending in the right direction
  • Good tolerance with manageable or absent side effects

Administration

How do I use N-Acetyl Selank?

Reconstitution

What you need

  • N-Acetyl Selank vial (lyophilized powder or solution)
  • Bacteriostatic water or sterile sodium chloride for reconstitution
  • Alcohol swabs for cleaning vial tops and injection sites
  • Appropriately sized syringes with fine-gauge needles (27-30 gauge)
  • Sharps disposal container

Injection

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

Storage

Before reconstitution

Store N-Acetyl Selank in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, N-Acetyl Selank should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation — discard the vial

  • Solution appears cloudy, discolored, or contains visible particles (should be clear)
  • Product has been exposed to temperatures outside the recommended storage range
  • Product has been frozen (unless specifically designed for freeze-thaw stability)
  • Expiration date has passed or reconstituted solution has exceeded its use-by date
  • Unusual odor, color change, or visible contamination

Sample daily schedule

  • As prescribed (once daily)

    As prescribed by your healthcare provider injection

    Site: Intranasal spray—rotate sites if applicable

    Maintain a consistent schedule for optimal results with N-Acetyl Selank. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is N-Acetyl Selank safe?

Side effects

Commonly reported: Nasal irritation, Transient headache, Mild drowsiness or fatigue, Vivid dreams, Appetite changes

Less common: Nasal congestion or epistaxis

Serious side effects

  • Allergic reaction

Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with N-Acetyl Selank
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

N-Acetyl Selank should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Flagged pairings

  • Benzodiazepines — additive GABAergic effects may cause excessive sedation (Selank enhances diazepam effects as shown in research) [3] — Use with caution—discuss with your healthcare provider.
  • Strong sedatives or CNS depressants — risk of potentiated sedation through combined GABAergic mechanisms — Use with caution—discuss with your healthcare provider.
  • Immunosuppressive drugs — may interfere with Selank's immunomodulatory properties — Use with caution—discuss with your healthcare provider.

Published research

What the studies show

  • Limited human trials
  • Research compound
  1. Neuropeptide mechanisms of action of Selank: molecular aspects of biological activity

    Vyunova TV, Andreeva LA, Shevchenko KV, Nagaev IY, Myasoedov NF · 2018PubMed

    Selank works like a master switch that controls anxiety by subtly tweaking brain receptors without the heavy sedation of traditional anxiety drugs. What makes it special is that it doesn't just calm your mood—it actually turns on the genes that build stronger, healthier brain connections, especially in the memory centers of your brain.

  2. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells

    Filatova EV, Shadrina MI, Slominsky PA · 2017PubMed

    Lab tests on human brain cells show that Selank turns on the exact genes that build calming brain receptors, proving it changes anxiety at the genetic level. This is completely different from how normal anxiety drugs work—those just activate existing receptors, while Selank actually increases how many calm-down receptors your brain makes.

  3. Selank Enhances the Effect of Diazepam: GABAA Receptor Subunit Study

    Kasian A, Kube E, Bhatt D · 2017PubMed

    Selank acts like a master key that makes anxiety drugs work harder and more smoothly at their brain receptors without changing the drugs themselves. When combined with the standard anxiety medication diazepam, Selank boosted its effects dramatically in laboratory tests, suggesting a powerful synergy between the two.

  4. Selank Administration Prevents the BDNF-Mediated Ethanol-Induced Memory Impairment

    Kolik LG, Nadorova AV, Seredenin SB · 2019PubMed

    Selank guards your brain's memory system against damage from alcohol by keeping the growth factor that protects brain cells (BDNF) at healthy levels even under stress. Animals given Selank showed dramatically preserved memory and learning ability compared to those without it, even when exposed to alcohol.

  5. Functional Connectomic Approach to Studying Selank and Semax Effects

    Panikratova YR, Lebedeva IS, Sokolov OY, et al. · 2020PubMed

    Brain scans of people taking Selank showed their brain networks rewired to be less reactive to anxiety triggers, with strengthened connections between the calm-down centers and weakened activity in the worry-processing areas. These visible brain changes confirm Selank actually reshapes how your brain processes anxiety at the network level.

  6. Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic Selank

    Medvedev VE, et al. · 2012DOI

    Intranasal Selank administered to patients with generalized anxiety disorder (reported up to 2700 mcg/day), with anxiolytic efficacy comparable to benzodiazepines without sedation or withdrawal.

  7. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo

    Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA · 2008DOI

    In male Wistar rats, intranasal Selank changed BDNF expression in the hippocampus, measured by RT-PCR and immunoenzyme assay. This is the only study measuring Selank's effect on BDNF; the primary text (Dokl Biol Sci 421:241-243) is paywalled, and it is cited for the BDNF-hippocampus link by later open-access work (Filatova 2017).

  8. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity

    Zozulya AA, Kost NV, Sokolov OY, et al. · 2001PubMed

    Patients with generalized anxiety showed a shortened enkephalin half-life and reduced total enkephalinase activity in blood. Selank dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin (IC50 15 microM), more potently than bacitracin or puromycin, which the authors propose as a mechanism of its anxiolytic activity.

  9. [Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank]

    Kolomin TA, Agapova TYu, Agniullin YaV, Shram SI, Shadrina MI, Slominsky PA, Limborska SA, Myasoedov NF · 2013PubMed

    A single intranasal dose of Selank (200 mcg/kg) changed mRNA levels of 36 genes more than 2-fold in rat hippocampus, and course administration changed 20; most encode plasma-membrane-associated proteins, suggesting regulation of ion homeostasis in hippocampal cells.

  10. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission

    Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P · 2016PubMed

    In rat frontal cortex, 45 of 84 neurotransmission genes (including GABAA receptor subunit, dopamine and serotonin receptor genes) changed expression 1 hour after Selank (300 mcg/kg) and 22 at 3 hours; the authors link Selank's mechanism to allosteric modulation of the GABAergic system. The paper also records Selank's development by the Institute of Molecular Genetics RAS in cooperation with the V.V. Zakusov Research Institute of Pharmacology.

  11. Selank® (Селанк®) — Instructions for medical use, Ministry of Health of the Russian Federation, registration ЛРС-003338/09

    Ministry of Health of the Russian Federation; JSC Peptogen (registration holder) · 2009peptogen.ru

    The approved Russian label for parent Selank: 0.15% nasal drops (75 mcg/drop), registered as an anxiolytic. Listed adverse effects are unpleasant taste sensations if solution reaches the pharynx and possible allergic reactions with individual intolerance; no overdose cases registered; no influence on CNS depressants or stimulants reported.

  12. [Experimental optimization of learning and memory processes by selank]

    Semenova TP, Kozlovskii II, Zakharova NM, Kozlovskaya MM · 2010PubMed

    In Wistar rats, a single injection of Selank (300 mcg/kg) activated serotonin metabolism in the hypothalamus and caudal brain stem for 30 min to 2 h and increased memory trace stability over 30 days; the authors attribute its nootropic activity to its effect on brain serotonin levels.

  13. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]

    Medvedev VE, Tereshchenko ON, Israelian AIu, Chobanu IK, Kost NV, Sokolov OIu, Miasoedov NF · 2014PubMed

    In 60 patients with phobic-anxiety and somatoform disorders, Selank showed pronounced anxiolytic and mild nootropic effects compared with the benzodiazepine phenazepam, with the anxiolytic effect lasting a week after the last dose and a positive impact on quality of life; the study was designed as an efficacy and tolerability comparison.

  14. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]

    Zozulya AA, Neznamov GG, Syunyakov TS, Kost NV, et al. · 2008PubMed

    In 62 patients with generalized anxiety disorder or neurasthenia (30 Selank, 32 medazepam), anxiolytic effects of the two drugs were similar, with Selank additionally antiasthenic and psychostimulant. Patients had a decreased leu-enkephalin half-life (tau1/2) in blood, and this parameter increased during Selank treatment, mostly in GAD.

  15. [A comparative analysis of distribution of glyprolines administered by various routes]

    Ashmarin IP, Baglikova KE, Edeeva SE, Zolotarev YuA, et al. · 2008PubMed

    Tritium-labelled Selank and Pro-Gly-Pro were tracked in rat tissues after intraperitoneal, intranasal, intragastric and intravenous administration; the intranasal route was shown to be optimal for delivering these peptide molecules to the central nervous system.

  16. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress

    Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB · 2003PubMed

    Across rat and mouse models of emotional stress created by a conflict situation, Selank and related tuftsin-family peptides showed positive emotional effects and antistress actions on behavioral manifestations of stress.

Head to head

N-Acetyl Selank compared

Want the full picture?

The complete N-Acetyl Selank research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.